Welcome to our dedicated page for Corbus Pharmaceu SEC filings (Ticker: CRBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin‑4 antibody‑drug conjugate CRB‑701 in second‑line oropharyngeal head and neck cancer (OPSCC) and cervical cancer. At the 3.6 mg/kg dose, confirmed objective response rates reached 42.9% in OPSCC and 34.4% in cervical cancer, with median durations of response of 6.3 and 8.0 months and progression‑free survival of 5.6 and 4.3 months, respectively.
Across 317 treated patients, CRB‑701 was generally well tolerated, with Grade 3 and 4 adverse events in 19.2% and 0.9%, no Grade 5 events, and treatment discontinuations of 2.8%. Ocular side effects were common but rarely led to discontinuation, and peripheral neuropathy was infrequent and mild.
Corbus plans to start a registrational TEMPO‑1 trial in 2L OPSCC in summer 2026 and has FDA alignment on randomized designs in both 2L OPSCC and 2L cervical cancer, supported by Fast Track designations. The company also highlighted early obesity data for oral CB1 inverse agonist CRB‑913, showing 2.9% placebo‑adjusted weight loss at day 14 in a 150 mg cohort.
Corbus Pharmaceuticals Holdings, Inc. reported that Chief Business Officer Nishant C. Saxena received new equity awards. On May 21, 2026, he was granted 58,300 restricted stock units (RSUs) that will settle in common shares, bringing his direct common stock holdings to 61,800 shares.
The RSUs vest 25% on each of the first four anniversaries beginning May 21, 2027, with partial acceleration possible if he is terminated without cause after the first vesting date. He was also granted options for 192,300 shares of common stock at an exercise price of $11.51 per share, expiring in 2036, which vest 25% on May 21, 2027 and the remaining 75% in equal monthly installments over 36 months starting June 21, 2027.
Corbus Pharmaceuticals Holdings, Inc. filed a Form 3 indicating that Chief Business Officer Nishant C. Saxena directly holds 3,500 shares of Common Stock, par value $0.0001 per share. This filing establishes his reported equity position as an officer of the company.
Corbus Pharmaceuticals director Winston Kung received new equity awards as part of his compensation. On May 19, 2026, he was granted 3,800 restricted stock units (RSUs), which will settle in common shares and vest 100% one year from the grant date. Following this award, his direct common stock holdings total 14,166 shares, including 8,600 unvested RSUs subject to their existing vesting schedules. On the same date, he also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest in full on the one-year anniversary of the grant.
Corbus Pharmaceuticals Holdings director Rachelle Suzanne Jacques received new equity awards. On May 19, 2026, she was granted 3,800 restricted stock units that will be settled in common shares and vest 100% one year after the grant date. The filing notes her common stock holdings total 11,383 shares, including 8,600 unvested RSUs subject to prior vesting schedules. She was also granted options to purchase 12,300 shares of common stock at an exercise price of $9.15 per share, which will vest 100% on the one-year anniversary of the grant, under the company’s 2024 Equity Compensation Plan.
Corbus Pharmaceuticals Holdings director John Kenneth Jenkins received new equity compensation. On May 19, 2026, he was granted 3,800 restricted stock units that will settle in common shares and vest 100% one year after the grant date. He was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which likewise vest fully on the one-year anniversary of grant under the company’s 2024 Equity Compensation Plan. Following these awards, his reported beneficial ownership is 8,633 shares of common stock, including 8,600 unvested RSUs subject to their vesting schedules.
Corbus Pharmaceuticals Holdings, Inc. director Anne Altmeyer reported equity compensation awards. On May 19, 2026, she received 3,800 restricted stock units (RSUs) that will vest 100% one year from the grant date and be settled in common shares. She was also granted stock options on 12,300 shares of common stock at an exercise price of $9.15 per share, which will likewise vest 100% after one year. Following the RSU grant, she directly holds 9,991 shares of common stock, and the disclosure notes this amount includes 8,600 unvested RSUs subject to prior vesting schedules.
Corbus Pharmaceuticals director Ben Yong received new equity awards as part of his compensation. On May 19, he was granted 3,800 restricted stock units that will convert into common shares after they vest in full one year from the grant date.
He also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest 100% after one year under the company’s 2024 Equity Compensation Plan. Following these awards, he directly holds 11,383 shares of common stock, including previously reported unvested RSUs.
Corbus Pharmaceuticals director Brent Pfeiffenberger received new equity awards as part of his compensation. On May 19, 2026, he was granted 7,500 restricted stock units that will settle in common shares and vest in three equal annual installments over three years, subject to continued service. He also received options on 24,700 shares of common stock at an exercise price of $9.15 per share, expiring on May 19, 2036, which will vest on the same three-year schedule under the company’s 2024 Equity Compensation Plan. Following these awards, his reported holdings include 7,500 shares of common stock and 24,700 stock options, all held directly.
Corbus Pharmaceuticals Holdings, Inc. director Brent Pfeiffenberger filed an initial ownership report on Form 3. The filing lists him as a director of the company but does not report any share transactions or holdings in this snapshot, serving as a baseline disclosure of his insider status.